Yang Wen-Wei, Yang Lin, Lu Hai-Zhen, Sun Yong-Kun
Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
World J Clin Cases. 2021 Oct 26;9(30):9134-9143. doi: 10.12998/wjcc.v9.i30.9134.
Pancreatic cancer (PC) is a leading cause of cancer-related death, given its poor prognosis and the limited benefits of traditional therapies. As tumors become more genetically disorganized as they progress, genetic mutations might become new markers for us to predict their behavior. Nowadays, many inhibitors can selectively target gene products as a form of targeted therapy, with some showing promise as treatment for various types of cancer.
We describe a rare case of a PC patient with long-term survival of more than 8 yr. The patient was diagnosed with pancreatic ductal adenocarcinoma (PDAC) with and gene mutations and fusion and achieved partial response twice after treatment with apatinib in combination with chemotherapy.
mutations, and fusion are rare in PDAC. Patients with these three gene alterations of PDAC may achieve long-term survival with apatinib. Further research in other contexts is needed to determine whether apatinib has ideal efficacy for PC treatment.
胰腺癌（PC）是癌症相关死亡的主要原因之一，因其预后较差且传统疗法的益处有限。随着肿瘤进展过程中基因变得更加紊乱，基因突变可能成为我们预测其行为的新标志物。如今，许多抑制剂可作为靶向治疗的一种形式选择性地作用于基因产物，其中一些在治疗各类癌症方面显示出前景。
我们描述了一例罕见的胰腺癌患者，其长期存活超过8年。该患者被诊断为伴有 和 基因突变以及 融合的胰腺导管腺癌（PDAC），在接受阿帕替尼联合化疗治疗后两次获得部分缓解。
在PDAC中罕见。具有这三种基因改变的PDAC患者使用阿帕替尼可能实现长期存活。需要在其他情况下进行进一步研究，以确定阿帕替尼对PC治疗是否具有理想疗效。
